Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells

被引:20
作者
Rutella, S
Bonanno, G
Procoli, A
Mariotti, A
Lucia, MB
Contemi, AM
Cauda, R
Fianchi, L
Scambia, G
Paganoa, L
Leone, G
机构
[1] Catholic Univ Med Sch, Dept Hematol, I-800168 Rome, Italy
[2] Catholic Univ Med Sch, Dept Gynecol, I-800168 Rome, Italy
[3] Catholic Univ Med Sch, Dept Infect Dis, I-800168 Rome, Italy
关键词
D O I
10.1016/j.exphem.2005.10.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the effects of granulocyte colony-stimulating factor (G-CSF) on the in vitro sensitivity of acute myeloid leukemia (AML) cell lines and primary AML blast cells to gemtuzumab ozogamicin (GO). Materials and Methods. AML cell lines and primary blasts from 10 patients with AML were first incubated for 72 hours in the presence of G-CSF (5 or 100 ng/mL) and then exposed to increasing concentrations of GO (1-1000 ng/mL) for an additional 72 hours. Results. Pretreatment with G-CSF translated into significant enhancement of GO-induced cytotoxicity in the GO-sensitive HL-60 and NB-4 cells. Conversely, the response of GO-insensitive KG-1a, TF-1, and K562 cells was unaffected by in vitro priming with G-CSF. In vitro exposure to G-CSF augmented GO-induced apoptosis in 7 of 10 primary AML samples and rendered blast cells from three refractory patients sensitive to killing effect of GO. The G-CSF-induced increase of the cytocidal activity of GO was independent of effects on the cell cycle and on the expression levels of CD33 antigen. Of potential interest, G-CSF induced dose-dependent inhibition of P-glycoprotein (P-gp/ABCB1) function in the GO-sensitive HL-60 and NB-4 cells and in blasts from three patients with AML that we tested. Conclusion. Collectively, our findings point to G-CSF as a potential sensitizing agent that can be exploited therapeutically to improve the clinical efficacy of GO. (c) 2006 International Society for Experimental Hematology.
引用
收藏
页码:54 / 65
页数:12
相关论文
共 38 条
[31]   Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse [J].
Sievers, EL ;
Larson, RA ;
Stadtmauer, EA ;
Estey, E ;
Löwenberg, B ;
Dombret, H ;
Karanes, C ;
Theobald, M ;
Bennett, JM ;
Sherman, ML ;
Berger, MS ;
Eten, CB ;
Loken, MR ;
van Dongen, JJM ;
Bernstein, ID ;
Appelbaum, FR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3244-3254
[32]  
SIVARAMAN SMJ, 2002, BLOOD, P100
[33]  
TAFURI A, 1994, LEUKEMIA, V8, P749
[34]   Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells [J].
van der Velden, VHJ ;
te Mervelde, JG ;
Hoogeveen, PG ;
Bernstein, ID ;
Houtsmuller, AB ;
Berger, MS ;
van Dongen, JJM .
BLOOD, 2001, 97 (10) :3197-3204
[35]   Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells [J].
Vitale, C ;
Romagnani, C ;
Falco, M ;
Ponte, M ;
Vitale, M ;
Moretta, A ;
Bacigalupo, A ;
Moretta, L ;
Mingari, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15091-15096
[36]   Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity [J].
Walter, RB ;
Raden, BW ;
Kamikura, DM ;
Cooper, JA ;
Bernstein, ID .
BLOOD, 2005, 105 (03) :1295-1302
[37]   The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin [J].
Walter, RB ;
Raden, BW ;
Cronk, MR ;
Bernstein, ID ;
Appelbaum, FR ;
Banker, DE .
BLOOD, 2004, 103 (11) :4276-4284
[38]   Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells [J].
Walter, RB ;
Raden, BW ;
Hong, TC ;
Flowers, DA ;
Bernstein, ID ;
Linenberger, ML .
BLOOD, 2003, 102 (04) :1466-1473